Philip Poortmans

Research interests

Publications

• Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.08.017

• Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.11.016

• Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.08.017

• ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.07.007

• Breast cancer

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(20)32381-3

• Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

  The Lancet Oncology · 2021 · 10.1016/s1470-2045(21)00288-6

• ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.03.284

• Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz173

• Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz235

• Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

  The Lancet · 2019 · 10.1016/s0140-6736(18)33137-4

• Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30777-5

• 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30067-5

• ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer

  Radiotherapy and Oncology · 2015 · 10.1016/j.radonc.2014.11.030

• Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1505949

• Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1415369

• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2015 · https://doi.org/10.1093/annonc/mdv298

• Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)71156-8

• Quality indicators in breast cancer care

  European Journal of Cancer · 2010 · https://doi.org/10.1016/j.ejca.2010.06.119

• Duration of Androgen Suppression in the Treatment of Prostate Cancer

  New England Journal of Medicine · 2009 · 10.1056/nejmoa0810095

• Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group

  Radiotherapy and Oncology · 2007 · https://doi.org/10.1016/j.radonc.2007.07.017

• Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2007.11.4991

• Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease

  New England Journal of Medicine · 2007 · 10.1056/nejmoa064601

• Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines

  Radiotherapy and Oncology · 2006 · 10.1016/j.radonc.2006.05.015

• Evaluation of Five Radiation Schedules and Prognostic Factors for Metastatic Spinal Cord Compression

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.04.754

• Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.13.524

• High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Non–AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962

  Journal of Clinical Oncology · 2003 · 10.1200/jco.2003.03.108

• Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation

  New England Journal of Medicine · 2001 · 10.1056/nejmoa010874

• The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial

  Radiotherapy and Oncology · 2000 · 10.1016/s0167-8140(00)00210-3

Current projects

No projects listed.